Profitability
This table compares Biotricity and PetVivo’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biotricity | -80.42% | N/A | -188.47% |
| PetVivo | -902.82% | -4,813.07% | -281.78% |
Institutional and Insider Ownership
3.9% of Biotricity shares are owned by institutional investors. Comparatively, 24.5% of PetVivo shares are owned by institutional investors. 10.1% of Biotricity shares are owned by company insiders. Comparatively, 10.8% of PetVivo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Biotricity and PetVivo”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biotricity | $12.06 million | 0.66 | -$14.09 million | ($0.16) | -1.75 |
| PetVivo | $1.05 million | 22.30 | -$10.95 million | ($0.38) | -1.74 |
PetVivo has lower revenue, but higher earnings than Biotricity. Biotricity is trading at a lower price-to-earnings ratio than PetVivo, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Biotricity has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, PetVivo has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.
Summary
Biotricity beats PetVivo on 7 of the 11 factors compared between the two stocks.
About Biotricity
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
About PetVivo
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Biotricity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotricity and related companies with MarketBeat.com's FREE daily email newsletter.
